Your browser is no longer supported. Please, upgrade your browser.
CNS Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own3.80% Shs Outstand27.44M Perf Week-11.41%
Market Cap29.82M Forward P/E- EPS next Y-0.53 Insider Trans0.84% Shs Float17.55M Perf Month-21.25%
Income-14.20M PEG- EPS next Q-0.14 Inst Own3.40% Short Float1.48% Perf Quarter-37.60%
Sales- P/S- EPS this Y-100.30% Inst Trans-27.11% Short Ratio1.24 Perf Half Y-50.14%
Book/sh0.33 P/B3.01 EPS next Y-12.10% ROA-104.10% Target Price6.25 Perf Year-57.96%
Cash/sh0.28 P/C3.59 EPS next 5Y- ROE-122.00% 52W Range0.89 - 4.46 Perf YTD-44.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.75% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low11.48% ATR0.10
Employees3 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)33.10 Volatility13.67% 8.98%
OptionableNo Debt/Eq0.00 EPS Q/Q-13.90% Profit Margin- Rel Volume0.95 Prev Close0.94
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume210.32K Price0.99
Recom2.00 SMA20-13.83% SMA50-24.89% SMA200-45.14% Volume199,055 Change5.55%
Dec-28-20Downgrade Ladenburg Thalmann Buy → Neutral
Aug-24-20Initiated Ladenburg Thalmann Buy $11
Dec-02-21 08:35AM  
Nov-16-21 08:00AM  
Nov-04-21 02:30PM  
Oct-11-21 08:00AM  
Sep-30-21 12:25PM  
Aug-15-21 03:41AM  
Aug-13-21 08:05AM  
Jul-12-21 07:30AM  
Jul-01-21 09:05AM  
Jun-29-21 10:19AM  
Jun-28-21 07:30AM  
Jun-17-21 09:05AM  
May-19-21 08:05AM  
May-14-21 09:05AM  
May-13-21 03:23AM  
May-11-21 08:35AM  
Mar-15-21 09:00AM  
Mar-04-21 09:00AM  
Feb-25-21 09:05AM  
Feb-24-21 07:30AM  
Feb-18-21 01:45PM  
Feb-04-21 11:53AM  
Jan-13-21 08:30AM  
Jan-07-21 08:30AM  
Dec-28-20 08:00AM  
Dec-23-20 08:30AM  
Dec-17-20 04:05PM  
Dec-16-20 08:30AM  
Nov-24-20 08:00AM  
Nov-19-20 08:00AM  
Nov-18-20 08:00AM  
Nov-17-20 08:00AM  
Nov-12-20 08:00AM  
Oct-29-20 08:00AM  
Oct-12-20 08:00AM  
Oct-09-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:00AM  
Sep-17-20 08:00AM  
Sep-11-20 08:00AM  
Sep-10-20 09:00AM  
Sep-03-20 08:00AM  
Aug-27-20 08:00AM  
Aug-25-20 08:39AM  
Aug-20-20 08:00AM  
Aug-11-20 08:00AM  
Jul-22-20 08:00AM  
Jul-15-20 08:00AM  
Jul-08-20 08:00AM  
Jun-30-20 08:00AM  
Jun-29-20 08:35AM  
Jun-23-20 08:49AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
May-28-20 08:00AM  
May-27-20 06:00PM  
May-18-20 08:48AM  
May-11-20 08:00AM  
May-08-20 05:10PM  
May-04-20 07:12PM  
Apr-30-20 08:00AM  
Apr-24-20 03:05AM  
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Downs ChristopherChief Financial OfficerDec 06Buy0.945,0004,702151,500Dec 07 08:30 AM
Downs ChristopherChief Financial OfficerNov 19Buy1.154,5005,192146,500Nov 22 08:47 AM